Viberzi denied as not FDA-approved for this use by Cigna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for viberzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Viberzi
## Why Cigna May Issue a Not-FDA-Approved Denial for Viberzi
A "not-FDA-approved" denial for Viberzi (eluxadoline) is unusual because eluxadoline does hold FDA approval for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. This type of denial most often arises in one of two situations: (1) the drug is being prescribed for an indication or population that falls outside the FDA-approved label — an "off-label" use — or (2) the denial represents an administrative or coding error in which Cigna's system misclassified an approved drug.
## Why This Denial Is Appealable
If the prescription is for the FDA-approved indication, the denial is factually incorrect and should be straightforward to reverse with documentation of the FDA label. If the use is off-label, federal law does not require insurers to cover off-label uses, but many plans do cover off-label uses that are supported by recognized compendia (such as Micromedex or Clinical Pharmacology) or major clinical guidelines — so the appeal should address whether Cigna's own policy covers compendia-supported off-label use.
## Your Federal Appeal Rights
Under ACA §2719, you are entitled to an internal appeal and then independent external review by an accredited IRO. Under ERISA §503, self-funded employer plans must conduct a full-and-fair review. The external-review window is generally approximately four months from the denial notice. Expedited review is available when standard timelines would jeopardize your health.
## The Appeal Process
1. Confirm the exact denial basis. Determine whether Cigna is claiming the drug itself is unapproved or that the specific use is off-label. Request the denial rationale and the policy number cited in writing. 2. Internal appeal. If for the on-label indication, attach the FDA-approved prescribing label. If off-label, attach compendia citations and your prescriber's medical-necessity letter. 3. External review. If denied internally, an IRO will independently assess whether the denial was clinically and legally appropriate.
## Documentation to Gather
- FDA prescribing label: Print or reference the current FDA-approved label confirming eluxadoline's approved indication and patient population.
- Prescriber's diagnosis confirmation: Chart notes establishing the on-label diagnosis (IBS-D) or, for off-label use, the clinical rationale and supporting evidence.
- Compendia support (if off-label): Citations from recognized drug compendia if the use falls outside the labeled indication.
- Prior treatment history: Documentation of earlier therapies to support medical necessity.
## Criteria-Mapping Structure
Request Cigna's coverage policy for eluxadoline. If the denial is administrative, a single letter citing the FDA label is often sufficient. For off-label situations, map each of Cigna's compendia or guideline requirements to a specific citation. Consult the FDA-approved prescribing label directly to confirm all relevant indications and to verify any eligibility criteria stated in the label.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →